1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Avecho Biotechnology Limited

Avecho Biotechnology Limited

AASX:AVE
0.02
AUD
+0.00
(-11.76%)
0.00EPS
33.06MMarket Cap
Mar 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.02
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.04
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
0.01
0.02
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
1,045
1,149
1,292
1,292
1,302
1,577
1,577
1,591
1,802
1,838
2,268
3,122
3,267
Sales/Revenue/Turnover
2
2
2
2
1
1
4
- -
1
1
- -
1
1
Operating Margin (%)
-1,117.32
-618.56
-644.52
-757.56
-853
-425.24
11.85
-885.8
-573.43
-247.64
-1,006.84
-437.79
-481.66
Depreciation Expense
4
4
3
2
1
1
1
1
- -
- -
- -
- -
- -
Net Income, GAAP
-13
-9
-20
-17
-9
-4
1
-3
-3
-2
-3
-3
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-789.6
-435.22
-918.72
-1,090.3
-742.84
-318.69
20.06
-685.04
-430.46
-194.2
-725.7
-275.64
-354.73
Working Capital
12
25
16
9
6
2
4
2
4
3
6
3
6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
41
49
29
12
6
4
5
3
5
2
6
3
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
8.99
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
19.67
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-24.52
-19.9
-51.62
-85.34
-94.66
-77.44
19.63
-71.08
-95.01
-67.06
-77.86
-64.72
-182.91

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.18%
16.85%
-52.3%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-57.19%
15.45%
41.47%
Sales/Revenue/Turnover
34.8%
49.34%
9.92%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
1
2025
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Paul David Gavin
Full Time Employees
15
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hallmarc Business Park Clayton VIC Australia 3168
IPO Date
Aug 9, 1993
Website
avecho.com.au
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Avecho Biotechnology Limited (ASX: AVE; OTC: AVEFF), a Melbourne-based biotechnology company founded in 1992 and headquartered in Clayton, Australia, develops, manufactures, sells and licenses innovative human and animal health products utilizing its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery technology, which enhances drug solubility, stability, bioavailability and transdermal absorption; core offerings include bulk TPM and Vital ET for pharmaceutical, cosmetic and nutraceutical formulations, licensed pain relief gels such as Voveran TPM Gel (Novartis India) and Instanac TPM Gel (Themis Medicare), transdermal patches and injectables for pain and dermatology applications including TPM/Oxymorphone and TPM/Oxycodone, oral and topical pharmaceutical cannabinoid products featuring a Phase III cannabidiol (CBD) TPM soft-gel capsule for insomnia treatment, edible cannabinoid gummies, non-antibiotic livestock feed additives to improve feed efficiency and animal health, and oncology drug formulations replacing toxic solvents with TPM. The company operates through Production, Human Health and other segments, with geographic focus spanning Australia, Switzerland, the Americas, India and additional international markets via licensing and partnerships. Formerly Phosphagenics Limited, it rebranded to Avecho Biotechnology Limited in May 2019; recent developments include a 2025 exclusive 10-year licensing agreement and US$3 million initial payment from Sandoz for commercializing the CBD insomnia capsule in Australia, a strategic alliance with Arthur Group LLC for TPM-enhanced versions of five leading oncology drugs, US patent allowance in 2025 for an optimized TPM manufacturing process, commencement of Phase III insomnia trial dosing with refined 2025 enrollment following 2024 recruitment insights, a major manufacturing campaign for US partner Ashland's Vital ET supply, and two-year stability achievement for the CBD capsule.

Company News

Company News APIChatGPT

  • gurufocus.com

    Positive interim analysis advances Avecho Phase III insomnia program

  • proactiveinvestors.com

    Avecho completes treatment phase for Phase III insomnia trial interim analysis